跳至主要内容
临床试验/ISRCTN14684459
ISRCTN14684459暂停未知

Comparing the mechanistic role of the carotid bodies in human heart failure with and without preserved ejection heart failure

niversity of Bristol0 个研究点目标入组 55 人开始时间: 2019年5月2日最近更新:
适应症

试验速览

阶段
未知
状态
暂停
发起方
入组人数
55

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • All participants:
  • 1. Aged 18-90 years
  • HFrEF participants:
  • As per the European Society of Cardiology (ESC) guidelines:
  • 1. Signs and symptoms of heart failure AND
  • 2. Raised natriuretic peptides AND
  • 3. Evidence of reduced ejection fraction (EF < 40%)
  • HFpEF participants:
  • As per the European Society of Cardiology (ESC) guidelines:
  • 1. Signs and symptoms of heart failure AND
  • 2. Raised natriuretic peptides (e.g. NTproBNP) AND
  • 3. Evidence of preserved ejection fraction (EF > 50%) AND
  • 4. Objective evidence of cardiac functional and structural alterations

排除标准

  • All participants:
  • 1. Requirement for oxygen therapy to maintain oxygen saturation
  • 2. Oxygen saturations at rest < 92%
  • 3. Chronic obstructive pulmonary disease (COPD) and known structural lung disease
  • 4. Current smoker (within the last 2 months)
  • 5. Acute coronary syndrome, coronary revascularisation or unstable angina in last 6 months
  • 6. HF related hospitalisation in the last 1 month.
  • 7. Transient ischaemic attack or stroke in the last 6 months
  • 8. Surgery under general anaesthesia in the last 3 months
  • 9. Change in regular medications within the last 1 month
  • 10. Clinically significant neurological disorder, including peripheral neuropathy
  • 11. Type 1 Diabetes Mellitus
  • 12. Heart transplant
  • 13. Haemodialysis or peritoneal dialysis
  • 14. Pregnancy, breast feeding or recent unprotected intercourse
  • 15. Palliative care/chemotherapy
  • 16. Recreational drug use and/or intravenous drug use
  • 17. Alcohol intake > 28 units/week
  • 18. Febrile illness/clinically significant infection within two weeks of participation
  • 19. Contraindications to dopamine administration:
  • 19.1. Known phaeochromocytoma
  • 19.2. Known hyperthyroidism
  • 19.3. Known uncontrolled atrial or ventricular tachyarrhythmias
  • 19.4. Known hypersensitivity to dopamine or any of the excipients
  • 19.5. Participants on the following medications:
  • 19.5.1. Monoamine oxidase I inhibitors
  • 19.5.2. Phenytoin
  • 19.5.3. Ergot alkaloids
  • 19.5.4. Tricyclic antidepressants
  • 19.5.5. Guanethidine
  • Healthy controls:
  • 1. No history of hypertension

研究者

发起方
niversity of Bristol

相似试验